EUVIMEDEUVIMED entdecken
Kommentar

Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis

Andrew Blauvelt, Curdin Conrad, Megan H Noe

JAMA Dermatology · 2024

DOI: 10.1001/jamadermatol.2024.2462 ↗

Kurz gefasst

Kommentar in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Andrew Blauvelt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Blauvelt Consulting, LLC, Lake Oswego, Oregon. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Drug Administration Schedule. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedDrug Administration ScheduleHumansTreatment OutcomeMaleFemaleMiddle AgedAdult

Substanzen

guselkumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Blauvelt Consulting, LLC, Lake Oswego, Oregon.
  • Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Zitieren

APA

Blauvelt, A., Conrad, C., & Noe, M. H. (2024). Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.2462

Vancouver

Blauvelt A, Conrad C, Noe MH. Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2024.2462

BibTeX
@article{Blauvelt2024,
  author = {Blauvelt, Andrew and Conrad, Curdin and Noe, Megan H},
  title = {Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis},
  journal = {JAMA Dermatology},
  year = {2024},
  doi = {10.1001/jamadermatol.2024.2462}
}
Kostenlos starten →